Navigation Links
Fox Chase researchers identify differences in treatments and outcomes of patients with second primary lung cancers versus those with one primary lung cancer

SAN FRANCISCO (August 1, 2009)Patients with second primary lung cancers (SPLC), when compared to those with one primary lung cancer (OPLC), are more likely to have localized disease at the time of diagnosis and are more likely to receive surgical treatment rather than radiation treatment. However, patients with SPLC have a 12% higher lung cancer specific mortality, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

"We want to identify factors that can improve and prolong lung cancer survivorship," says Linna Li, M.D., resident physician in the radiation department at Fox Chase.

It is recognized that patients who were previously treated for lung cancer are at high risk of developing SPLC, but the impact of this second cancer on treatment and lung cancer specific mortality is unknown. With this study Li and her colleagues aimed to uncover some of these unknowns.

The study used the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) database and evaluated the treatment and outcomes of non-small cell lung cancer (NSCLC) survivors with SPLC. Survivors of at least 2 years, over the age of 18 and undergoing active follow-up were included. With a median follow-up of 7 years, 49,577 patient with OPLC and 2,914 patients with SPLC were identified. The incidence, tumor characteristics, treatment, and cause of death in patients with OPLC and SPLC were analyzed.

"By studying a large population database, we can get important information to guide recommendations for treatment and follow up."

The research showed that median time to develop a second cancer is 51 months with 28% diagnosed 5 years after initial diagnosis of lung cancer. When diagnosed with OPLC versus SPLC, localized disease was 45% versus 60%, loco-regional disease was 35% versus 32%, and metastatic disease was 14% versus 5%. The data also showed that treatment of OPLC versus SPLC was 68% versus 87% with surgery, 31% versus 20% with radiation therapy, and 12% versus 12% with both surgery and radiation therapy. At the time of the last follow up, 56% of OPLC and 67% of SPLC were deceased. The leading cause of death in patients with OPLC versus SPLC was 64% versus 76% from lung cancershowing that those with SPLC have a 12% higher lung cancer specific mortality.

"Curing second primary lung cancers is crucial in the long term care of lung cancer survivors. We should continue to follow lung cancer survivors after 5 years to detect second cancers earlier. It's unclear why SPLC are more likely to die from lung cancer even though they present with earlier disease. Perhaps they have less reserve, limited treatment options for the second treatment, or simply, that they are older. We need to study this more carefully in future clinical trials." adds Li.


Contact: Diana Quattrone
Fox Chase Cancer Center

Related medicine news :

1. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
2. Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent(TM) Portfolio License
3. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program
4. Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid
5. Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio
6. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
7. ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of Health
8. Turkish Ministry of Health Purchases Two CyberKnife(R) Systems
9. CorVel Corporation to Adopt 10b5-1 Stock Repurchase Plan
10. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
11. Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
Post Your Comments:
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the first ... annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the International ... November 11th, 2015. The conference was held at the Hawaii Convention Center in ...
(Date:11/25/2015)... IN (PRWEB) , ... November 25, 2015 , ... ... water accessible for all, Water For Empowerment ™ attracts volunteers together who ... clean water by empowering women as key stakeholders in the process. The non-profit ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical ... more about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared ... thicker and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... 25, 2015 , ... Lakeview Health, a Jacksonville-based drug and ... sobriety and show through pictures what a positive difference it makes. The social ... the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  The total global healthcare industry is expected to ... Latin America has the highest projected growth ... Japan ), is second with growth projected at ... increased healthcare expenditure. In 2013-2014, total government funded healthcare was ... 2008-2009 to 41.2% in 2013-2014. In real terms, out of ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
Breaking Medicine Technology: